SAN DIEGO, Feb. 08, 2016 (GLOBE NEWSWIRE) -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycans, today announced the close of a $5 million financing. This financing included both existing and new individual investors and provides SENTÉ with a sizable cash balance to fuel expansion and continued company growth.
“We are very pleased to continue seeing such strong investor interest in our company from leading experts in the healthcare and aesthetic field,” said Kleanthis G. Xanthopoulos, Ph.D., SENTÉ Co-Founder and Board Member. “Our investors share our vision in creating unique science based dermatological products that will have profound impacts on the skin, and we very much look forward to continued growth in this endeavor."
The Company, which realized top line year over year growth of 266%, will use this financing to increase its domestic sales force, support the launch of new and innovative products, pursue international expansion and invest behind meaningful new technologies.
“We are excited about the significant progress SENTÉ made in 2015 and we are equally pleased with the continued financial support of our investors,” said Faheem Hasnain, Chairman of the Board of SENTÉ. “We look forward to an exciting year in 2016 with continued strong revenue growth.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through our exclusive network of physicians and medically supervised spas.